Neoadjuvant anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) treatment of cisplatin-ineligible patients with urothelial cancer (UC) had higher density TLS in pretreatment tumor specimens of responders (R) associated with longer recurrence-free survival (RFS) and OS (115). The gene discussed is CTLA4; the disease is neoplasm.